Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Non-invasive Lung Disease Study of Exhaled Breath Nitric Oxide Based on Ultraviolet Differential Absorption Spectroscopy Techniques.
J Biophotonics
January 2025
Clinical Research Center for Respiratory Disease (Tumor) in Anhui Province, Bengbu, Anhui Province, China.
In this study, a non-invasive device based on ultraviolet differential absorption spectroscopy (UV-DOAS) technology for detecting fractional exhaled nitric oxide (FeNO)was developed and clinically validated in patients with various lung diseases. The diagnostic potential of FeNO was explored by analysing subgroups of patients with lung cancer, nodules, and other disease. The results showed that FeNO concentrations were significantly higher in patients with malignant tumours than in healthy controls (p < 0.
View Article and Find Full Text PDFIntroduction: Elexacaftor/tezacaftor/ivacaftor (ETI) has shown significant improvements in pulmonary and nutritional status in persons with cystic fibrosis (pwCF). Less is known about the extrapulmonary impact of ETI and effects on airway microbiology, lung clearance index (LCI) and fraction of exhaled nitric oxide (FeNO).
Methods: A multicentre prospective observational trial, including 79 pwCF ≥ 18 years eligible for ETI.
Retrospective Study of the Impact of SARS-CoV-2 Infection on Asthma Control in Children.
J Clin Med
January 2025
Department of Pediatrics "Mother and Child", Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Asthmatic children who tested positive for COVID-19 experienced changes in lung function and persistent symptoms following SARS-CoV-2 infection, even for several months after diagnosis, and with the same features as in an acute phase. This study aimed to analyze a pediatric age group (between 0 and 17 years old) diagnosed with asthma, and SARS-CoV-2 infection attending regular monitoring visits in a Pediatric Department of a Regional Tertiary Hospital (Filantropia Clinical Municipal Hospital Craiova, Romania) during the COVID-19 pandemic and post-pandemic time interval (i.e.
View Article and Find Full Text PDFEfficacy Assessment of Biological Treatments in Severe Asthma.
J Clin Med
January 2025
Department of Pneumology, Hospital La Paz, Universidad Autónoma de Madrid, IdiPAZ, and CIBER of Respiratory Diseases, 28046 Madrid, Spain.
Uncontrolled, severe asthma remains a significant clinical challenge, affecting a small proportion of asthma patients worldwide. Despite advancements in treatment options, a subset of patients continues to experience frequent exacerbations, uncontrolled symptoms, and impaired quality of life. The advent of biological therapies has revolutionized the management of severe asthma, offering targeted treatments that address specific inflammatory pathways.
View Article and Find Full Text PDFInhaled corticosteroids in asthma and chronic obstructive pulmonary disease combined phenotype: when to use and what to expect?
Monaldi Arch Chest Dis
January 2025
Department of Community Medicine, K.S. Hegde Medical College, Deralakatte, Karnataka.
The term "asthma-chronic obstructive pulmonary disease (COPD) combined phenotype" describes patients with persistent airflow limitation and features of both asthma and COPD. There is a lack of data on effective treatments for this group, often excluded from asthma or COPD trials. Inhaled corticosteroids (ICS) are standard for asthma, while bronchodilators are key for COPD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!